title: The EP3 Agonist Sulprostone Enhances Platelet Adhesion But Not Thrombus Formation Under Flow Conditions.
abstract: Platelets express the EP2, EP3 and EP4 receptors. Prostaglandin (PG) E2 has a biphasic effect on platelets. Low concentrations of PGE2 enhance platelet aggregation through the activation of the EP3 receptors, while at high concentrations it attenuates aggregation via the EP4 receptor. Consequently, EP3 receptor inhibition was shown to inhibit artherothrombosis, but had no influence on bleeding time in vivo. In this study, we investigated the role of the EP3 receptor in adhesion and thrombus formation under flow conditions in vitro. The EP3 agonist sulprostone caused an increase in the adhesion of washed platelets to fibrinogen as well as to collagen under low shear stress, an effect that was blocked by the EP3 antagonist L-798106. In contrast, when whole blood was perfused over collagen-coated surfaces, sulprostone did not enhance binding and thrombus formation of platelets on collagen; at high concentrations it even attenuated this response. We conclude that in more physiological models of thrombus formation, the role for EP3 receptors is limited, indirectly suggesting that the primary action of PGE2 in haemostasis might be an inhibitory one.
authors.affiliation: Institute of Experimental and Clinical Pharmacology, Medical University of Graz, Graz, Austria.
authors.forename: Lisa
authors.initials: L
authors.lastname: Pasterk
authors.forename: Sonia
authors.initials: S
authors.lastname: Philipose
authors.forename: Kathrin
authors.initials: K
authors.lastname: Eller
authors.forename: Gunther
authors.initials: G
authors.lastname: Marsche
authors.forename: Akos
authors.initials: A
authors.lastname: Heinemann
authors.forename: Rufina
authors.initials: R
authors.lastname: Schuligoi
mesh_terms: D001792:Blood Platelets / Q000187:drug effects / Q000378:metabolism*; D003094:Collagen / Q000494:pharmacology; D015232:Dinoprostone / Q000031:analogs & derivatives* / Q000494:pharmacology; D005340:Fibrinogen / Q000494:pharmacology; D006801:Humans; D066298:In Vitro Techniques; D010973:Platelet Adhesiveness / Q000187:drug effects*; D010974:Platelet Aggregation / Q000187:drug effects; D058308:Receptors, Prostaglandin E, EP3 Subtype / Q000819:agonists*; D013449:Sulfonamides / Q000494:pharmacology; D013927:Thrombosis / Q000097:blood* / Q000139:chemically induced; D000096926:Benzenesulfonamides
chemical_list: D003094:Collagen; D015232:Dinoprostone; D005340:Fibrinogen; D058308:Receptors, Prostaglandin E, EP3 Subtype; D013449:Sulfonamides; C000595268:5-bromo-2-methoxy-N-(3-(naphthalen-2-yl-methylphenyl)acryloyl)benzenesulfonamide; D000096926:Benzenesulfonamides; C016767:sulprostone